News

Get the latest from Biologics

We invite you to learn more about our work. Check out our organization’s recent news, and browse our press releases to see what we’ve been doing. You can also check out upcoming events in which we’ll be participating or read more about our how we give back to our community.

Biologics’ Patient Access Services Team Procures more than $44 Million in Co-pay Assistance for Cancer Patients in 2016

CARY, N.C. (May 24, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, secured more than $44 million in co-pay assistance in 2016 for commercial patients in need of oral chemotherapy drugs, easing the financial burden for these patients battling cancer. The Biologics’ Patient Access Services team also referred more than 38,000 unique patients to… Read More

IMFINZI (durvalumab) Approved for Previously Treated Patients with Advanced Bladder Cancer, Available Immediately at Biologics, Inc.

CARY, N.C. (May 22, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by AstraZeneca to be a specialty pharmacy provider in the limited distribution network for IMFINZITM (durvalumab). In addition to being available via specialty distribution, IMFINZI can also be dispensed by Biologics as a specialty pharmacy option. Approved… Read More

ALUNBRIG (brigatinib) Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.

CARY, N.C. (May 10, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc., to be a specialty pharmacy provider as part of the distribution network for ALUNBRIGTM (brigatinib). ALUNBRIG, an oral therapy for the treatment of patients wit… Read More

RYDAPT® (midostaurin) Approved for the Treatment of FLT3-Mutated Acute Myeloid Leukemia, Available for Order at Biologics, Inc.

CARY, N.C. (May 3, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Novartis to be in the distribution network for RYDAPT® (midostaurin), a new oral treatment for adults with newly-diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. The AML treatment strategy has remained virtually… Read More

Biologics, Inc. Selected by TESARO as a Specialty Pharmacy Provider for ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

CARY, N.C. (April 21, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by TESARO, Inc. to be a specialty pharmacy provider in the distribution network for ZEJULATM (niraparib). Approved by the U.S. Food and Drug Administration (FDA) on March 27, 2017, ZEJULA is a poly ADP-ribose polymerase (PARP) inhibitor,… Read More

BAVENCIO® (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics, Inc.

CARY, N.C. (March 28, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by EMD Serono to be a specialty pharmacy provider for BAVENCIO (avelumab). Approved by the U.S. Food and Drug Administration (FDA) on March 23, 2017, BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for t… Read More

KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, available for order at Biologics, Inc.

CARY, N.C. (March 17, 2017) —Biologics, Inc. a McKesson Specialty Health oncology pharmacy services company, has been selected by Novartis to be a specialty pharmacy provider for KISQALI® (ribociclib). Approved by the U.S. Food and Drug Administration (FDA) on March 13, 2017, KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as… Read More

XERMELO (telotristat ethyl) Approved for the Treatment of Carcinoid Syndrome, Available for Order Immediately at Biologics, Inc.

CARY, N.C. (March 1, 2017) —Biologics, Inc. has been selected by Lexicon Pharmaceuticals to be a specialty pharmacy provider in the limited distribution network for XERMELO (telotristat ethyl). Approved by the U.S. Food and Drug Administration (FDA) on February 28, 2017, XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea… Read More

RUBRACA (rucaparib) Approved for the Treatment of Advanced Ovarian Cancer, Available Immediately at Biologics, Inc.

CARY, N.C. (December 19, 2016) —Biologics, Inc. has been selected by Clovis Oncology, Inc. to be a specialty pharmacy provider in the limited distribution network for RUBRACATM (rucaparib). Approved by the U.S. Food and Drug Administration (FDA) on December 19, 2016, RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment… Read More

CABOMETYX (cabozantinib) Tablets Approved for Advanced Renal Cell Carcinoma, available at Biologics, Inc.

CARY, N.C. — October 3, 2016 —Biologics, Inc. has been selected by Exelixis, Inc. to be a specialty pharmacy provider in the limited distribution network for CABOMETYXTM (cabozantinib) tablets. Approved by the U.S. Food and Drug Administration (FDA) on April 25, 2016, CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma… Read More